

Members Obtain Free CE Credits from JCP Articles!



Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review

April 2021 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a global health concern. Currently, some therapies and vaccines have received US Food & Drug Administration approval or emergency use authorization for the management of COVID-19. According to the pathophysiology of the disease, several medications have been evaluated in different clinical conditions of the disease. Evidence-based reviews and categorization of these medications can guide the clinicians to select the proper medications according to each patient's condition. Therefore, this review was performed to categorize COVID-19 potential therapeutics and vaccines.



Joint Accreditation Statement

In support of improving patient care, the American College of Clinical Pharmacology® (ACCP) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

UAN: JA4008220-0000-21-017-H01-P– ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this Journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists and PhDs.

Learning Objectives

After completing this activity, the learner will be able to:

1. Explain the virology and immunology of the SARS-CoV-2 virus;
2. List medications that have shown a strong benefit in their respective medication classes, i.e., interferons, steroids, biologics, etc.;
3. Discuss the rationale as to why some medications should not be used in treatment or prevention due to a greater risk to the patient with minimal to no benefit;
4. Compare SARS-CoV-2 investigation vaccines and explain the pros/cons for each product.

Requirements to Receive Credit

In order to receive continuing education credit, the learner must register for the educational activity, study the provided journal article and complete the online learning Post-event Self-assessment, as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: Joseph S. Bertino Jr, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc. Nothing to disclose.

Planner: Alexander J. Sperry, BS, PharmD Student, School of Pharmacy, Medical Coll of Wisconsin. Nothing to disclose.

CE Reviewer: Sonia Pahwa, PhD, Clinical Pharmacology Reviewer, CDER/OTS/OCP/DIDP, US Food & Drug Administration. Nothing to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 04/01/2021

Expiration Date: 12/31/2023

Helpful Tips

Download the article and access the Self-assessment Post-test, Evaluation and Certificate [here](#).

Learn how to print your CME/CPE Certificate [here](#).
